Topical olopatadine versus placebo in allergic conjunctivitis
Introduction:
Worldwide, allergic conjunctivitis is a common ocular morbidity with the prevalence of 5% to 22%. At present, topical medications for allergic conjunctivitis consist of topical antihistamines, mast cell stabilizers, eosinophil deactivators, lubricants, and cyclosporine ophthalmic solution and for severe disease; topical corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) are essential. Olopatadine is a dual-action, selective H1-receptor antagonist and a mast cell stabilizer.
Objective:
This systemic review aims to assess the safety and efficacy of topical olopatadine versus placebo and other topical anti-allergic medications in treating allergic conjunctivitis.
Method: …show more content…
The safety and efficacy of topical olopatadine was analysed using meta-analysis.
Results:
• The study reported that topical olopatadine is associated with a pooled-mean difference (MD) inocular itch of –1.33 (P < 0.00001) and ocular hyperemia of –0.92 (P < 0.00001) than placebo.
• Olopatadine was inferior to alcaftadine on ocular itch (pooled-MD = 0.39; P< 0.00001) but comparable with epinastine and ketotifen.
Introduction:
Worldwide, allergic conjunctivitis is a common ocular morbidity with the prevalence of 5% to 22%. At present, topical medications for allergic conjunctivitis consist of topical antihistamines, mast cell stabilizers, eosinophil deactivators, lubricants, and cyclosporine ophthalmic solution and for severe disease; topical corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) are essential. Olopatadine is a dual-action, selective H1-receptor antagonist and a mast cell stabilizer.
Objective:
This systemic review aims to assess the safety and efficacy of topical olopatadine versus placebo and other topical anti-allergic medications in treating allergic conjunctivitis.
Method: …show more content…
The safety and efficacy of topical olopatadine was analysed using meta-analysis.
Results:
• The study reported that topical olopatadine is associated with a pooled-mean difference (MD) inocular itch of –1.33 (P < 0.00001) and ocular hyperemia of –0.92 (P < 0.00001) than placebo.
• Olopatadine was inferior to alcaftadine on ocular itch (pooled-MD = 0.39; P< 0.00001) but comparable with epinastine and ketotifen.